From cells to people.
Developing the path from pioneering cellular research to human applications of partial reprogramming.
Life,reprogrammed.
We were early.
We’re here for
what comes next.
199 is a biotechnology company built on pioneering work in partial reprogramming.
We are building on that foundation to change how we approach aging and disease. Our next chapter brings together human application and a commitment to making advanced therapies accessible to more people.
Our storyExtraordinary science.
A human future.
Our next programmes are taking shape in stealth. Two ambitions guide the work.
From possibility to access.
Democratising partial reprogramming and gene therapies, with access built into our thinking from the start.
The science
behind the ambition.
Reprogramming is our foundation. A wider body of work informs how we think about healthier, longer lives.
An early conviction.
A long view.
199 began with a conviction: partial reprogramming could open a new chapter in how we approach aging and disease.
Founded by Boris Djordjevic, we carry that conviction into our work today: advancing the science toward human application and democratising access to reprogramming and gene therapies.
We work closely with Triple Helix and Dr. Patrick Sewell as we pursue the next chapter in reprogramming and gene therapies.
Meet Triple Helix